Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

1.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators.

Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.

2.

Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban.

Harenberg J, Jörg I, Fenyvesi T, Piazolo L.

J Thromb Thrombolysis. 2005 Feb;19(1):65-9. Erratum in: J Thromb Thrombolysis. 2005 Oct;20(2):137. Job, Harenberg [corrected to Harenberg, Job]; Ingrid, Jörg [corrected to Jörg, Ingrid]; Tivadar, Fenyvesi [corrected to Fenyvesi, Tivadar]; Lukas, Piazolo [corrected to Piazolo, Lukas].

PMID:
15976970
3.

Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin.

Fischer KG, Liebe V, Hudek R, Piazolo L, Haase KK, Borggrefe M, Huhle G.

Thromb Haemost. 2003 Jun;89(6):973-82.

PMID:
12783109
4.

Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.

Harenberg J, Zokai K, Piazolo L, Fenyvesi T, Jörg I.

Semin Thromb Hemost. 2002 Aug;28(4):379-82.

PMID:
12244485
5.
6.
7.
8.

[Low-molecular-weight heparins. The prevention and therapy of thromboembolic diseases].

Harenberg J, Huhle G, Piazolo L, Malsch R.

Hautarzt. 1997 Nov;48(11):852-64. Review. German. No abstract available.

PMID:
9518253
9.

Anticoagulation in patients with heparin-induced thrombocytopenia type II.

Harenberg J, Huhle G, Piazolo L, Wang LU, Heene DL.

Semin Thromb Hemost. 1997;23(2):189-96.

PMID:
9200346
10.

Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin.

Harenberg J, Huhle G, Piazolo L, Giese C, Heene DL.

Semin Thromb Hemost. 1997;23(2):167-72.

PMID:
9200342
11.

Comparison of the pharmacodynamic and pharmacokinetic profiles of two low-molecular-mass heparins in rats.

Piazolo L, Harenberg J, Malsch R, Hüttner FG, Heene DL.

Semin Thromb Hemost. 1997;23(2):109-17.

PMID:
9200334
12.

Measurement of fluorescent-labeled LMM-heparin in biological fluids using protamine-linked microbeads.

Malsch R, Melui D, Piazolo L, Harenberg J, Heene DL.

Semin Thromb Hemost. 1997;23(1):23-30.

PMID:
9156407
13.

Chromatographic and electrophoretic applications for the analysis of heparin and dermatan sulfate.

Malsch R, Harenberg J, Piazolo L, Huhle G, Heene DL.

J Chromatogr B Biomed Appl. 1996 Oct 25;685(2):223-31.

PMID:
8953163
14.

Preferential binding of heparin to granulocytes of various species.

Harenberg J, Malsch R, Piazolo L, Huhle G, Heene DL.

Am J Vet Res. 1996 Jul;57(7):1016-20.

PMID:
8807013
15.

Analysis of heparin binding to human leukocytes using a fluorescein-5-isothiocyanate labeled heparin fragment.

Harenberg J, Malsch R, Piazolo L, Huhle G, Heene DL.

Cytometry. 1996 Jan 1;23(1):59-66.

PMID:
14650442
16.
17.
18.

Binding of fluorescent-labeled low molecular mass heparin to latex microspheres and to rat and human leukocytes.

Piazolo L, Harenberg J, Malsch R, Heene DL.

Semin Thromb Hemost. 1994;20(3):227-35.

PMID:
7824956
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk